Aliashrafi Soodabeh, Arefhosseini Seyed Rafie-, Lotfi-Dizaji Lida, Ebrahimi-Mameghani Mehrangiz
Student Research Committee, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutritional Biochemistry, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Health Promot Perspect. 2019 Oct 24;9(4):263-269. doi: 10.15171/hpp.2019.36. eCollection 2019.
Due to inconsistent evidence regarding the potential role of vitamin D on lipid profile and sirtuin 1 (SIRT-1), this study was designed to investigate the effect of vitamin D supplementation in combination with weight loss diet on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency. Forty-four obese subjects with vitamin D deficiency were randomly assigned in a randomized clinical trial to receive either a weight reduction diet supplemented with 50000IU vitamin D3 pearl (n = 22) or placebo (n = 22) once weekly for 12 weeks. Changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) and SIRT-1 were the primary outcomes. Secondary outcomes were changes in body mass index (BMI), 25(OH) D and parathyroid hormone (PTH). Physical activity and dietary intakes were also assessed. During the intervention, PTH (mean difference, -33.36; 95% CI: -49.15 to -17.57;P<0.001) and LDL-C (mean difference, -15.91; 95% CI: -21.76 to -10.07; P<0.001) decreased and 25(OH) D (mean difference, 36.44; 95% CI: 29.05 to 43.83; P<0.001) increased significantly in the vitamin D group. BMI (mean differences: -2.40; 95% CI: [-2.92 to-1.88] in vitamin D group and mean differences: -1.90; 95% CI [-6.58 to -3.01] in placebo group, P<0.05 for both groups), TC (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001 in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) and TG (mean difference,-21.31; 95% CI: -27.24 to -15.38; P<0.001in vitamin D group and mean difference, -12.54; 95% CI: -19.02 to -6.06; P<0.001 in placebo group) decreased and SIRT-1(mean difference, 3.95; 95% CI: 1.18 to 6.73; P=0.007in vitamin D group and mean difference,1.91; 95% CI: 0.31 to 3.63 in placebo group, P=0.022) increase significantly in both group. At end of the study, 25(OH) D and PTH showed significant differences in between-group analyses(P<0.05). No significant difference was detected for HDL-C in within and between groups. This study gives no support for any beneficial effect of vitamin D supplementation on lipid profile and SIRT-1 in obese subjects with vitamin D deficiency.
由于关于维生素D对血脂谱和沉默调节蛋白1（SIRT - 1）潜在作用的证据不一致，本研究旨在探讨补充维生素D联合减肥饮食对维生素D缺乏的肥胖受试者血脂谱和SIRT - 1的影响。在一项随机临床试验中，44名维生素D缺乏的肥胖受试者被随机分配，一组每周一次接受补充50000IU维生素D3软胶囊的减肥饮食（n = 22），另一组接受安慰剂（n = 22），为期12周。总胆固醇（TC）、低密度脂蛋白胆固醇（LDL - C）、甘油三酯（TG）、低高密度脂蛋白胆固醇（HDL - C）和SIRT - 1的变化是主要观察指标。次要观察指标为体重指数（BMI）、25（OH）D和甲状旁腺激素（PTH）的变化。同时评估身体活动和饮食摄入情况。在干预期间，维生素D组的PTH（平均差值，-33.36；95%CI：-49.15至-17.57；P<0.001）和LDL - C（平均差值，-15.91；95%CI：-21.76至-10.07；P<0.001）降低，2五十羟维生素D（平均差值，36.44；95%CI：29.05至43.83；P<0.001）显著升高。BMI（维生素D组平均差值：-2.40；95%CI：[-2.92至-1.88]，安慰剂组平均差值：-1.90；95%CI [-6.58至-3.01]，两组P<0.05）、TC（维生素D组平均差值，-21.31；95%CI：-27.24至-15.38；P<0.001，安慰剂组平均差值，-12.54；95%CI：-19.02至-6.06；P<0.001）和TG（维生素D组平均差值，-21.31；95%CI：-27.24至-15.38；P<0.001，安慰剂组平均差值，-12.54；95%CI：-19.02至-6.06；P<0.001）均降低，SIRT - 1（维生素D组平均差值，3.95；95%CI：1.18至6.73；P = 0.007，安慰剂组平均差值，1.91；95%CI：0.31至3.63；P = 0.022）在两组中均显著升高。在研究结束时，25（OH）D和PTH在组间分析中显示出显著差异（P<0.05）。HDL - C在组内和组间均未检测到显著差异。本研究不支持补充维生素D对维生素D缺乏的肥胖受试者血脂谱和SIRT - 1有任何有益作用。
